AlphaHelix Presents AmpXpress(TM) at the BIOTECHNICA Show

UPPSALA, Sweden, October 5 /PRNewswire-FirstCall/ --
- A New Miniaturized PCR Instrument With SuperConvection(TM)
- At One Sixth the Price of QuanTyper(TM) Without Loss of Performance
- Next Generation of PCR Expected to Rapidly Penetrate the Market
AlphaHelix (Ticker: ALPH) has in a very short time developed a
miniaturized PCR-instrument - AmpXpress(TM) - to meet demands for lower
instrument prices. This was made possible through know-how obtained during
the development of QuanTyper(TM). AmpXpress(TM) is substantially smaller in
size and weight, silent, consumes less power and will attract customers that
are looking for a fast, simple and easy to use PCR-instrument with
SuperConvection(TM). AlphaHelix expects a rapid penetration of the market as
the price of AmpXpress(TM) is comparable to low-end thermal cyclers (without
a rotary format). The sales price of AmpXpress(TM) is only one sixth of the
price of QuanTyper(TM) (the first version of AmpXpress(TM) is however a
standard PCR instrument, and does not feature real-time detection (qPCR).
AmpXpress(TM) will be presented tomorrow at the BIOTECHNICA show in Hannover,
Germany.
More information about AmpXpress(TM) is found at
http://www.alphahelix.com. The product development has cost approximately 500
KSEK (gross). AlphaHelix has also been granted 250 KSEK by the Swedish Agency
for Economic and Regional Growth. A first series of ten instruments has been
initiated and patent applications have been submitted.
Technology assessment of SuperConvection and QuanTyper(TM) proceeds at
the American biotechnology company and is not affected by the launch of
AmpXpress(TM). Results from the evaluation are expected early November, at
the earliest.
AlphaHelix Molecular Diagnostics AB (publ) develops instruments for rapid
DNA analysis. The company's patented technology enables identification of
virus and bacteria faster and with greater sensitivity than other technology
available on the market. The AlphaHelix share is traded at AktieTorget
http://www.aktietorget.se, which is a multilateral trading facility for small
caps under the supervision of the Swedish Financial Supervisory Authority.
SOURCE AlphaHelix Molecular Diagnostics AB

For more information, please contact: Lars Edvinsson, CEO, phone
+46-768-302-304, or Per Ersson, CFO, phone +46-708-66-24-45